Literature DB >> 17626270

Increased susceptibility to liver injury in hepatitis B virus transgenic mice involves NKG2D-ligand interaction and natural killer cells.

Yongyan Chen1, Haiming Wei, Rui Sun, Zhongjun Dong, Jian Zhang, Zhigang Tian.   

Abstract

UNLABELLED: The innate immunopathogenesis responsible for the susceptibility to hepatocyte injury in chronic hepatitis B surface antigen carriers is not well defined. In this study, hepatitis B virus (HBV) transgenic mice (named HBs-Tg) were oversensitive to liver injury after immunologic [polyinosinic:polycytidylic acid or concanavalin A (ConA)] or chemical (CCl4) triggering. It was then found that the nonhepatotoxic low dose of ConA for wild-type mice induced severe liver injury in HBs-Tg mice, which was dependent on the accumulated intraheptic natural killer (NK) cells. Expressions of NKG2D ligands (Rae-1 and Mult-1) in hepatocytes were markedly enhanced upon ConA stimulation in HBs-Tg mice, which greatly activated hepatic NK cells via NKG2D/Rae-1 or Mult-1 recognition. Interestingly, the presence of NK T cells was necessary for NK cell activation and worked as positive helper cell possibly by producing interferon-gamma and interleukin-4 in this process.
CONCLUSION: Our findings for the first time suggested the critical role of NKG2D recognition of hepatocytes by NK cells in oversensitive liver injury during chronic HBV infection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17626270     DOI: 10.1002/hep.21872

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  57 in total

Review 1.  Effect of NKG2D ligand expression on host immune responses.

Authors:  Marine Champsaur; Lewis L Lanier
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

Review 2.  Roles of liver innate immune cells in nonalcoholic fatty liver disease.

Authors:  Yu-Tao Zhan; Wei An
Journal:  World J Gastroenterol       Date:  2010-10-07       Impact factor: 5.742

Review 3.  Evolutionary struggles between NK cells and viruses.

Authors:  Lewis L Lanier
Journal:  Nat Rev Immunol       Date:  2008-03-14       Impact factor: 53.106

Review 4.  Natural killer cells in immunodefense against infective agents.

Authors:  Nicolas Zucchini; Karine Crozat; Thomas Baranek; Scott H Robbins; Marcus Altfeld; Marc Dalod
Journal:  Expert Rev Anti Infect Ther       Date:  2008-12       Impact factor: 5.091

5.  Role natural killer group 2D-ligand interactions in hepatitis B infection.

Authors:  Teresa Pollicino; Lemonica Koumbi
Journal:  World J Hepatol       Date:  2015-04-28

Review 6.  The role of innate immunity in HBV infection.

Authors:  Qiuju Han; Cai Zhang; Jian Zhang; Zhigang Tian
Journal:  Semin Immunopathol       Date:  2012-07-20       Impact factor: 9.623

7.  CD137-mediated pathogenesis from chronic hepatitis to hepatocellular carcinoma in hepatitis B virus-transgenic mice.

Authors:  Jun Wang; Wenxia Zhao; Liang Cheng; Mingzhou Guo; Dongling Li; Xiaozhu Li; Yi Tan; Suping Ma; Suyun Li; Yunsheng Yang; Lieping Chen; Shengdian Wang
Journal:  J Immunol       Date:  2010-11-08       Impact factor: 5.422

8.  Blockade of NKG2D on NKT cells prevents hepatitis and the acute immune response to hepatitis B virus.

Authors:  Sílvia Vilarinho; Kouetsu Ogasawara; Stephen Nishimura; Lewis L Lanier; Jody L Baron
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-08       Impact factor: 11.205

9.  Activation of innate immunity (NK/IFN-gamma) in rat allogeneic liver transplantation: contribution to liver injury and suppression of hepatocyte proliferation.

Authors:  Kezhen Shen; Shu-Sen Zheng; Ogyi Park; Hua Wang; Zhaoli Sun; Bin Gao
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-02-21       Impact factor: 4.052

10.  Changes to the natural killer cell repertoire after therapeutic hepatitis B DNA vaccination.

Authors:  Daniel Scott-Algara; Maryline Mancini-Bourgine; Hélène Fontaine; Stanislas Pol; Marie-Louise Michel
Journal:  PLoS One       Date:  2010-01-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.